Page Description

View meeting statistics and demographic information for the 2021 Annual Meeting.

Body

2021 Registration Numbers

  • Total: 32,950

  • Professionals: 30,200

  • Exhibitors: 1,800

  • Media and Others: 950

  • Domestic Professional Attendees: 14,150

  • International Professional Attendees: 16,050

Top 10 Countries in Attendance in 2021

  • United States: 14,150

  • United Kingdom: 1,130

  • Japan: 1,099

  • Germany: 1,096

  • Spain: 1,072

  • France: 1,004

  • Brazil: 982

  • Canada: 797

  • Italy: 658

  • Mexico: 628

Primary Professional Role in 2021

Percentages reflect the portion of those who responded that included a specific answer

Responded: 53%
No Response:47%
Totals: 30,200

  • Medical Oncologist: 14%

  • Clinical Oncologist: 13%

  • Researcher: 6%

  • Oncology Fellow Resident: 6%

  • Medical Science Liaison: 4%

  • Hematologic Oncologist: 3%

  • Consultant: 2%

  • Pharmacist: 2%

  • Patient Advocate 2%

  • Pharmaceutical Sales Representative: 2%

  • Biologist: 2%

  • Medical Resident: 2%

  • Surgical Oncologist: 1%

  • Gynecologic Oncologist: 1% 

  • Medical Student: 1% 

  • Financial Service Representative: 1%

  • Radiation Oncologist: 1% 

  • Pediatric Oncologist: 1%

Primary Interest in 2021

Percentages reflect the portion of those who responded that included a specific answer

Responded: 53%
No Response: 47%
Totals: 30,200

  • Clinical Trials: 35%

  • Lung Cancer: 33%

  • Breast Cancer: 33%

  • Developmental Therapeutics - Immunotherapy: 24%

  • Developmental Therapeutics - Moleculary Targeted Agents and Tumor Biology: 23%

  • Gastrointestinal - Colorectal: 21%

  • Gastrointestinal - Gastroesophageal, Pancreatic, and Hepatobiliary: 20%

  • Hematologic Malignancies - Lymphoma and CLL: 15%

  • Genitourinary Cancer - Prostate, Testicular, and Penile: 14%

  • Hematologic Malignancies - Leukemia, MDS, and Allotransplant: 12%

  • Genitourinary Cancer - Kidney and Bladder: 11%

  • Gynecologic Cancer: 10%

  • Head and Neck Cancer: 10%

  • Melanoma and Skin Cancers: 9%

  • Hematologic Malignancies - Plasma Cell Dyscrasia: 8%

  • Disparities and Health Equity: 7%

  • Symptoms and Survivorship: 6%

  • Sarcoma: 5%

  • Cancer Prevention, Risk Reduction, and Genetics: 5%

  • Health Services Research and Quality Improvement: 5%

  • Professional Development and Education Advances: 5%

  • Central Nervous System Tumors: 4%

  • Global Health: 4%

  • Care Delivery and Regulatory Policy: 4%

  • Pediatric Oncology: 3%

  • Geriatric Oncology: 3%

  • Value: 3%